...
首页> 外文期刊>Microvascular Research: An International Journal >Homocysteine up-regulates endothelin type A receptor in vascular smooth muscle cells through Sirt1/ERK1/2 signaling pathway
【24h】

Homocysteine up-regulates endothelin type A receptor in vascular smooth muscle cells through Sirt1/ERK1/2 signaling pathway

机译:通过SIRT1 / ERK1 / 2信号通路,同型半胱氨酸型内皮蛋白在血管平滑肌细胞中造成的受体

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Abstract Sirtuin 1 (Sirt1) is a longevity gene that has protective effects in cardiovascular diseases (CVDs). The endothelin type A (ET A ) receptor is involved in pathogenesis of CVDs. The extracellular signal related kinases 1 and 2 (ERK1/2) signaling pathway is involved in regulation of the ET A receptor induced by some CVD risk factors in vascular smooth muscle cells (VSMCs). Hyperhomocysteinemia (HHcy) is an independent risk factor for CVDs. The present study was designed to investigate the hypothesis that homocysteine up-regulates ET A receptor through the Sirt1/ERK1/2 signaling pathway. In vitro experiments were performed in the rat superior mesenteric artery. The rat superior mesenteric artery was cultured with or without homocysteine (Hcy) in the presence and absence of Resveratrol (Res, a Sirt1 agonist), SRT1720 (a specific Sirt1 agonist) or U0126 (an ERK1/2 signaling pathway inhibitor) in serum-free medium for 24 h. In vivo, the rats received subcutaneous injections of Hcy in the presence of or absence of Res or U0126 for 3 weeks. The contractile response to ET-1 was studied using a sensitive myograph. In addition, the level of protein expression was determined using western blotting. Hcy significantly increased the expression of ET A receptor and also increased the ET A receptor-mediated contractile response induced by ET-1 in vitro. These effects were inhibited by Res, SRT1720 and U0126 treatment. In addition, Hcy down-regulated the level of Sirt1, and up-regulated the level of phosphorylated ERK1/2, which was reversed upon Res or SRT1720 treatment. In vivo results showed that HHcy results in the up-regulation of ET A receptor expression, and elevated blood pressure in rats. However, Res and U0126 could block these effects, respectively. In conclusion, these results suggest that Hcy regulates ET A receptor expression via the Sirt1/ERK1/2 signaling pathway in VSMCs. Highlights ? Hcy up-regulated ETA receptor protein expression in VSMCs by down-regulating Sirt1. ? Sirt1/ERK1/2 pathway is involved in Hcy-induced-up-regulation of ETA receptor. ? Hcy up-regulated blood pressure through Sirt1/ERK1/2/ETA receptor pathway.
机译:摘要Sirtuin 1(Sirt1)是一种寿命基因,具有心血管疾病(CVDS)的保护作用。内皮素型A(等)受体参与CVDS的发病机制。细胞外信号相关激酶1和2(ERK1 / 2)信号传导途径参与由血管平滑肌细胞(VSMCs)中的一些CVD危险因子诱导的ET A受体的调节。 HyperHomysteinemia(HHCy)是CVDS的独立危险因素。本研究旨在探讨通过SIRT1 / ERK1 / 2信号通路的同型半胱氨酸上调等的假设。在大鼠优质肠系膜中进行体外实验。在血清中存在和不存在白藜芦醇(Res,SIRT1激动剂),SRT1720(特异性SIRT1 Agonist)或U0126(ERK1 / 2信号传导途径抑制剂),在存在和没有同型肠系膜(HCY)中培养或不含同型肠系膜的动脉(Hcy)培养。 24小时的游离培养基。在体内,大鼠在res或u0126的情况下检查了Hcy的皮下注射3周。使用敏感的Imograph来研究对ET-1的收缩响应。此外,使用蛋白质印迹测定蛋白质表达水平。 Hcy显着增加了等受体的表达,并且还增加了ET-1在体外诱导的受体介导的收缩反应。这些效果被RES,SRT1720和U0126治疗抑制。此外,Hcy下调SIRT1的水平,并上调磷酸化ERK1 / 2的水平,其在RES或SRT1720处理时逆转。在体内结果表明,HHCY导致ET对ET的上调和大鼠血压升高。然而,RES和U0126分别可以分别阻止这些效果。总之,这些结果表明Hcy通过VSMCS中通过SIRT1 / ERK1 / 2信号传导途径调节ET受体表达。强调 ? Hcy上调的ETA受体蛋白表达在VSMC中,通过下调SIRT1。还SIRT1 / ERK1 / 2途径参与了ETA受体的HCY诱导调节。还Hcy上调血压通过SIRT1 / ERK1 / 2 / ETA受体途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号